WORLD PEPTIDEFOUNDATION

Where is Tesamorelin being studied?

Find registered human studies, phases, products, recruitment status and reported research locations around the world. Registry search matches are separate from this profile’s reviewed evidence.

Find studies for Tesamorelin →Worldwide registry directory
Search this profile’s alternative names

Check the intervention identity in each registry record; aliases and combination products can produce broader matches.

Scientific intelligence record

Experience 2.0

Growth hormone-releasing hormone analog

Tesamorelin

Also known as: Egrifta, Egrifta SV, TH9507

Tesamorelin is a stabilized N-terminally modified analog of the 44-amino-acid human growth hormone–releasing hormone. It activates pituitary GHRH receptors, increasing endogenous growth-hormone release and downstream IGF-1 signaling. In the labeled population this pathway reduces visceral adipose tissue; it is not a general weight-loss mechanism.

Record status

Traceability partial

Last meaningful update: 9/9/2026

Evidence searched through:
Not recorded
Assessment updated:
9/9/2026
Documented human review:
9/8/2026
Automated scientific assessment:
None recorded
AI source check:
9/26/2026

Published source links and profile text pass separate gates. Only a documented human review is labelled as human review; an automated scientific assessment applies deterministic checks, and an AI source check confirms only that a source exists and matches its identifiers. A source count alone does not establish a review.

Evidence coverage has three distinct layers. The corpus count is a transparent screening inventory, the featured set contains study-level tiering and interpretation, and the published-source count contains records promoted through the institutional publication workflow. Source validation, editorial publication, and scientific appraisal are separate decisions; these numbers must not be merged.

Ranked research corpus

104

Categorized publications with provisional ranking; scientific review remains separate.

Featured tiered studies

26

Cornerstone publications with study-level interpretation, limitations, and tier disclosure.

Research domains

13

Clinical and scientific questions synthesized independently across the evidence atlas.

Published source records

25

Database records promoted through the governed publication workflow—not the corpus total.

Corpus generated 2026-09-18. Counts remain separately labeled so screening is not represented as completed review.

Human experience · separate evidence stream

No community pattern is displayed yet

Eligible observations remain below the privacy and reliability threshold. WPF will not convert a handful of reports into a percentage, trend, or clinical claim.

Observation is valuable human context. It is not evidence of causation, efficacy, or safety.

Public display gate

n ≥ 20 eligible observations

Exact progress remains private before the threshold.

Contribute an observationArchive details

Intelligence snapshot

The state of the record

A compact view of what is represented, what remains unresolved, and how completely the record can be traced.

Ranked research corpus

104

Categorized screening records; proposed rankings remain pending human appraisal.

Featured tiered studies

26

Cornerstone studies with published study-level interpretation and tier disclosure.

Research domains

13

Independent evidence dossiers covering the major research questions.

Published source records

25

Source records published through the governed workflow; this count does not certify scientific conclusions.

Contradictions

0

Conflicting evidence relationships that remain visible.

Research gaps

1

Questions the current record identifies as unresolved.

Connected media

0

Media records explicitly linked to this scientific record.

What we know

Evidence, claims, and boundaries

The project separates represented evidence from qualification, contradiction, uncertainty, and what the evidence does not establish.

Reconciled domain conclusions

13 published domain syntheses connected to 26 featured studies

Tesamorelin no longer relies on the legacy “no public claim” state. Each research domain publishes a bounded synthesis, confidence level, evidence context, limitations, geographic applicability, regulatory interpretation, and research gaps. Publication of these syntheses is separate from the scientific review status shown above.

Inspect the reconciled evidence atlas
Inspect the published evidence record25 governed records · titles, provenance, and original-source linksOpen records ↓
2025FDA-approved clinical use
Evidence strength A+ · 95/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Automated baseline based on evidence tier; full-text risk-of-bias review may revise it

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

EGRIFTA (tesamorelin acetate) prescribing information, revised March 2025

Current US labeling limits the indication to reduction of excess abdominal fat in adults with HIV and lipodystrophy; it is not indicated for weight-loss management.

Source
official_product_labeling
Open original source
2011Phase 3 human evidence
Evidence strength A · 91/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
18/100
Directness
15/100
Reporting quality
10/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction.

To report the effects of tesamorelin, a growth hormone-releasing hormone analogue, on inflammatory and fibrinolytic markers and to relate these effects to changes in visceral adipose tissue (VAT). Four hundred and ten HIV-infected patients with abdominal adiposity were randomized to 2 mg tesamorelin (n = 273) or placebo (n = 137) subcutaneously daily for 26 weeks. Circulating plasminogen activator inhibitor-1 (PAI-1) antigen, tissue plasminogen activator (tPA) antigen, C-reactive protein (CRP), and adiponectin were assessed. At baseline, VAT was significantly associated with PAI-1 antigen (ρ = 0.36, P < 0.001), tPA antigen (ρ = 0.29, P < 0.001), CRP (ρ = 0.18, P < 0.001), and adiponectin...

Authors
Takara L Stanley, Julian Falutz, Jean-Claude Mamputu, Graziella Soulban, Diane Potvin, Steven K Grinspoon
Source
peer_reviewed_research
DOI
10.1097/QAD.0b013e328347f3f1
PubMed
21516030
Open original source
2012Phase 3 human evidence
Evidence strength A · 91/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
18/100
Directness
15/100
Reporting quality
10/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.

Tesamorelin, a growth hormone-releasing hormone analogue, decreases visceral adipose tissue (VAT) by 15%-20% over 6-12 months in individuals with human immunodeficiency virus (HIV)-associated abdominal adiposity, but it is unknown whether VAT reduction is directly associated with endocrine and metabolic changes. In 2 phase III, randomized, double-blind studies, men and women with HIV-associated abdominal fat accumulation were randomly assigned (ratio, 2:1) to receive tesamorelin or placebo for 26 weeks. At week 26, patients initially receiving tesamorelin were randomly assigned to continue receiving tesamorelin or to receive placebo for an additional 26 weeks. In per-protocol analysis of...

Authors
Takara L Stanley, Julian Falutz, Christian Marsolais, Josée Morin, Graziella Soulban, Jean-Claude Mamputu, Hani Assaad, Ralph Turner
Source
peer_reviewed_research
DOI
10.1093/cid/cis251
PubMed
22495074
Open original source
2007Phase 3 human evidence
Evidence strength A · 90/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Automated baseline based on evidence tier; full-text risk-of-bias review may revise it

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Metabolic Effects of a Growth Hormone–Releasing Factor in Patients with HIV

A randomized phase 3 trial found that 26 weeks of tesamorelin reduced visceral adipose tissue and improved selected lipid measures in adults with HIV-associated abdominal fat accumulation.

Source
peer_reviewed_research
DOI
10.1056/NEJMoa072375
PubMed
18003959
Open original source
2010Phase 3 human evidence
Evidence strength A · 90/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Automated baseline based on evidence tier; full-text risk-of-bias review may revise it

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension

A randomized trial and extension reported about an 18% visceral-fat reduction and improvement in body-image distress during treatment.

Source
peer_reviewed_research
PubMed
20101189
Open original source
2014Phase 1–2 human evidence
Evidence strength A · 86/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
18/100
Directness
15/100
Reporting quality
10/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH.

Few studies have assessed the relationship between GH and mitochondrial function. The objective of this study was to determine the effects of improving IGF-I using a GHRH analog, tesamorelin, on mitochondrial function assessed by phosphocreatine (PCr) recovery using (31)P magnetic resonance spectroscopy in obese adults with reduced GH. A total of 39 obese men and women with reduced GH secretion as determined by GHRH-arginine stimulation tests underwent magnetic resonance spectroscopy as part of a 12-month, double-blind, randomized, placebo-controlled trial comparing tesamorelin vs placebo. PCr recovery after submaximal exercise was assessed at baseline and at 12 months. At baseline,...

Authors
Hideo Makimura, Caitlin A Murphy, Meghan N Feldpausch, Steven K Grinspoon
Source
peer_reviewed_research
DOI
10.1210/jc.2013-3436
PubMed
24178787
Open original source
2015Phase 1–2 human evidence
Evidence strength A · 86/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
18/100
Directness
15/100
Reporting quality
10/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects.

Tesamorelin is a synthetic analogue of growth hormone-releasing factor (GRF), which increases basal and pulsatile growth hormone (GH) secretion and subsequently increases insulin-like growth factor (IGF)-1. Limited information is available about the pharmacokinetics of this compound. Consequently, the aim of this study was to characterize the population pharmacokinetics of tesamorelin in HIV-infected patients and healthy subjects. A total of 38 HIV-infected patients and healthy subjects receiving subcutaneous tesamorelin doses of 1 or 2 mg administered daily during 14 consecutive days were included in the analysis. An open one-compartment model with first- and zero-order absorption and...

Authors
Mario González-Sales, Olivier Barrière, Pierre Olivier Tremblay, Fahima Nekka, Jean-Claude Mamputu, Sylvie Boudreault, Mario Tanguay
Source
peer_reviewed_research
DOI
10.1007/s40262-014-0202-x
PubMed
25358450
Open original source
2017Phase 1–2 human evidence
Evidence strength A · 86/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
18/100
Directness
15/100
Reporting quality
10/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial.

Use of growth hormone is associated with side effects, including insulin resistance. The objective of this study was to determine whether tesamorelin, a stabilized growth hormone-releasing hormone analogue, would alter insulin sensitivity or control of diabetes. A 12-week randomized, placebo-controlled study of 53 patients with type 2 diabetes. Three treatment groups: placebo, 1 and 2 mg tesamorelin. Fasting glucose, glucose and insulin from oral glucose tolerance test, glycosylated hemoglobin (HbA1c), home blood glucose, insulin-like growth factor-1, and lipids. Relative insulin response following oral ingestion of glucose. No significant differences were observed between groups in...

Authors
David R Clemmons, Sam Miller, Jean-Claude Mamputu
Source
peer_reviewed_research
DOI
10.1371/journal.pone.0179538
PubMed
28617838
Open original source
2015Phase 1–2 human evidence
Evidence strength A · 86/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
18/100
Directness
15/100
Reporting quality
10/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Population pharmacokinetic and pharmacodynamic analysis of tesamorelin in HIV-infected patients and healthy subjects.

The objective of this analysis was to characterize the time course of selected pharmacodynamic (PD) markers of tesamorelin: growth hormone (GH) and insulin-like growth factor (IGF-1) concentrations in HIV-infected patients and healthy volunteers. A total of 41 subjects in Phase I trials receiving subcutaneous daily doses of 1 or 2 mg of tesamorelin during 14 consecutive days were included in this analysis. A previous pharmacokinetic (PK) model of tesamorelin was used as the input function for the PD model of GH. Tesamorelin was hypothesized to stimulate the secretion of GH in an "episodic" manner, i.e., for a finite duration of time. The resulting PK/PD model of GH was used to describe...

Authors
Mario González-Sales, Olivier Barrière, Pierre Olivier Tremblay, Fahima Nekka, Jean-Claude Mamputu, Sylvie Boudreault, Mario Tanguay
Source
peer_reviewed_research
DOI
10.1007/s10928-015-9416-2
PubMed
25895899
Open original source
2008Phase 1–2 human evidence
Evidence strength A · 86/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
18/100
Directness
15/100
Reporting quality
10/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.

Treatment of HIV patients with daily tesamorelin, a growth hormone-releasing factor analogue, for 26 weeks resulted in a significant decrease in visceral adipose tissue (VAT) and improvement in lipids. The objective of the 26-week extension phase was to evaluate long-term safety and effects of tesamorelin. HIV patients with central fat accumulation in the context of antiretroviral therapy were randomized to tesamorelin 2 mg (n = 273) or placebo (n = 137) s.c. daily for 26 weeks. At week 26, patients originally on tesamorelin were rerandomized to 2 mg tesamorelin (T-T group, n = 154) or placebo (T-P group, n = 50), whereas patients originally on placebo were switched to tesamorelin (P-T...

Authors
Julian Falutz, Soraya Allas, Jean-Claude Mamputu, Diane Potvin, Donald Kotler, Michael Somero, Daniel Berger, Stephen Brown
Source
peer_reviewed_research
DOI
10.1097/QAD.0b013e32830a5058
PubMed
18690162
Open original source
2015Phase 1–2 human evidence
Evidence strength A · 86/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
18/100
Directness
15/100
Reporting quality
10/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat.

Tesamorelin, a synthetic analog of human growth hormone-releasing factor, decreases visceral adipose tissue (VAT) in human immunodeficiency virus (HIV)-infected patients with lipodystrophy. 1) To evaluate the utility of patient characteristics and validated disease-risk scores, namely indicator variables for the metabolic syndrome defined by the International Diabetes Federation (MetS-IDF) or the National Cholesterol Education Program (MetS-NCEP) and the Framingham Risk Score (FRS), as predictors of VAT reduction during tesamorelin therapy at 3 and 6 months, and 2) To explore the characteristics of patients who reached a threshold of VAT <140 cm2, a level associated with lower risk of...

Authors
Alexandra Mangili, Julian Falutz, Jean-Claude Mamputu, Miganush Stepanians, Brooke Hayward
Source
peer_reviewed_research
DOI
10.1371/journal.pone.0140358
PubMed
26457580
Open original source
2019Phase 1–2 human evidence
Evidence strength A · 86/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
18/100
Directness
15/100
Reporting quality
10/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV.

Tesamorelin, a growth hormone-releasing hormone analogue, decreases visceral adipose tissue in people living with HIV, however, the effects on skeletal muscle fat and area are unknown. The goals of this exploratory secondary analysis were to determine the effects of tesamorelin on muscle quality (density) and quantity (area). Secondary, exploratory analysis of two previously completed randomized (2:1), clinical trials. U.S. and Canadian sites. People living with HIV and with abdominal obesity. Tesamorelin participants were restricted to responders (visceral adipose tissue decrease ≥8%). Tesamorelin or placebo. Computed tomography scans (at L4-L5) were used to quantify total and lean...

Authors
S Adrian, A Scherzinger, A Sanyal, J E Lake, J Falutz, M P Dubé, T Stanley, S Grinspoon
Source
peer_reviewed_research
DOI
10.14283/jfa.2018.45
PubMed
31237318
Open original source
2024Phase 1–2 human evidence
Evidence strength A · 86/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
18/100
Directness
15/100
Reporting quality
10/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors.

Tesamorelin is the only FDA-approved therapy to treat abdominal fat accumulation in people with HIV (PWH). Phase III clinical trials were conducted prior to the introduction of integrase inhibitors (INSTIs), which are now a mainstay of HIV antiretroviral therapy. We leveraged a randomized double-blind trial of 61 PWH and metabolic dysfunction-associated steatotic liver disease to evaluate the efficacy and safety of tesamorelin 2 mg once daily vs. identical placebo among participants on INSTI-based regimens at baseline. In the parent clinical trial, visceral fat cross-sectional area, hepatic fat fraction, and trunk-to-appendicular fat ratio were quantified using magnetic resonance...

Authors
Samuel C Russo, Mollie W Ockene, Allison K Arpante, Julia E Johnson, Hang Lee, Mabel Toribio, Takara L Stanley, Colleen M Hadigan
Source
peer_reviewed_research
DOI
10.1097/QAD.0000000000003965
PubMed
38905488
Open original source
2020Phase 1–2 human evidence
Evidence strength A · 86/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
18/100
Directness
15/100
Reporting quality
10/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD.

Nonalcoholic fatty liver disease (NAFLD) is a common comorbidity among people living with HIV that has a more aggressive course than NAFLD among the general population. In a recent randomized placebo-controlled trial, we demonstrated that the growth hormone-releasing hormone analog tesamorelin reduced liver fat and prevented fibrosis progression in HIV-associated NAFLD over 1 year. As such, tesamorelin is the first strategy that has shown to be effective against NAFLD among the population with HIV. The current study leveraged paired liver biopsy specimens from this trial to identify hepatic gene pathways that are differentially modulated by tesamorelin versus placebo. Using gene set...

Authors
Lindsay T Fourman, James M Billingsley, George Agyapong, Shannan J Ho Sui, Meghan N Feldpausch, Julia Purdy, Isabel Zheng, Chelsea S Pan
Source
peer_reviewed_research
DOI
10.1172/jci.insight.140134
PubMed
32701508
Open original source
2025Phase 1–2 human evidence
Evidence strength A · 86/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
18/100
Directness
15/100
Reporting quality
10/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity.

In people with HIV who are virally suppressed with antiretroviral therapy, abdominal obesity (AO) is linked to neurocognitive impairment (NCI), potentially due to visceral adiposity, inflammation, and reduced insulin-like growth factor 1 (IGF-1). Tesamorelin, a growth hormone-releasing hormone, reduces AO and increases IGF-1, suggesting that it might mitigate NCI in people with HIV and viral suppression. This 6-month phase 2 randomized open-label clinical trial compared tesamorelin vs standard of care (SOC) for NCI in people with HIV who were virally suppressed and abdominally obese (elevated waist circumference [WC]). Exclusions included conditions other than HIV causing NCI, active...

Authors
Ronald J Ellis, Florin Vaida, Keren Hu, Michael Dube, Brook Henry, Felicia Chow, Robert K Heaton, Daniel Lee
Source
peer_reviewed_research
DOI
10.1093/infdis/jiaf012
PubMed
39813152
Open original source
2012Phase 1–2 human evidence
Evidence strength B+ · 82/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Automated baseline based on evidence tier; full-text risk-of-bias review may revise it

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial

A 20-week randomized trial reported favorable composite cognition and executive-function signals, increased IGF-1, and more adverse events than placebo.

Source
peer_reviewed_research
DOI
10.1001/archneurol.2012.1970
PubMed
22869065
Open original source
2019Phase 1–2 human evidence
Evidence strength B+ · 82/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Automated baseline based on evidence tier; full-text risk-of-bias review may revise it

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial

A multicentre randomized trial found reduced hepatic fat and less fibrosis progression over 12 months in people with HIV and NAFLD.

Source
peer_reviewed_research
DOI
10.1016/S2352-3018(19)30338-8
PubMed
31611038
Open original source
2014Phase 1–2 human evidence
Evidence strength B+ · 82/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Automated baseline based on evidence tier; full-text risk-of-bias review may revise it

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial

A small randomized trial found reductions in visceral adipose tissue and hepatic lipid over six months; early fasting glucose increased but six-month glucose differences were not significant.

Source
peer_reviewed_research
DOI
10.1001/jama.2014.8334
PubMed
25038357
Open original source
2026Observational human evidence
Evidence strength A · 83/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
18/100
Directness
15/100
Reporting quality
10/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Efficacy and Safety of Tesamorelin in People Living With HIV (PLWH) With Lipodystrophy: A Systematic Review and Meta-Analysis.

BackgroundHIV-associated lipodystrophy, a complication of combined antiretroviral therapy (CART), causes significant physical and psychological distress in people living with HIV (PLWH), compromising treatment adherence. Tesamorelin, a growth hormone-releasing hormone (GHRH) analogue, has emerged as a therapeutic option.ObjectiveTo systematically evaluate the efficacy and safety of tesamorelin in HIV-infected individuals with lipodystrophy receiving CART, incorporating GRADE assessment.MethodsWe searched PubMed, https://ClinicalTrials.gov, and Scopus from inception to February 9, 2026, for randomized controlled trials evaluating tesamorelin in HIV-associated lipodystrophy. Mean...

Authors
Aqsa Mohammed Ditta, Ruqaiya Muhammad Naeem, Muhammad Mohsin Sami, Muhammad Abdul Rafey, Hunain Ali, Muhammad Waqar Amjad, Fahad Jahangir, Kehan Ali Rizvi
Source
systematic_review_or_meta_analysis
DOI
10.1177/23259582261475549
PubMed
42538058
Open original source
2026Observational human evidence
Evidence strength A · 83/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
18/100
Directness
15/100
Reporting quality
10/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials.

HIV-associated lipodystrophy leads to visceral fat accumulation, metabolic complications, body image concerns, medication non-adherence, and increased cardiovascular risks. We thought to assess the effects of Tesamorelin, a synthetic growth hormone-releasing hormone analogue, that has been proposed as a targeted therapy. We systematically searched PubMed, Embase, Scopus, Web of Science, and CENTRAL through July 2025 for randomized controlled trials (RCTs) evaluating Tesamorelin versus placebo in adults with HIV. Random-effects meta-analysis was applied. Outcomes included changes in body composition, hepatic and metabolic parameters, hormonal markers, and adverse events. Risk of bias was...

Authors
Ahmed Samy Badran, Abdulrhman Helal, Karim Samir Shata, Hazem Ayesh
Source
systematic_review_or_meta_analysis
DOI
10.1016/j.orcp.2026.01.002
PubMed
41545261
Open original source
2011Insufficient evidence
Evidence strength B · 68/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
18/100
Directness
15/100
Reporting quality
10/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Spotlight on tesamorelin in HIV-associated lipodystrophy.

Tesamorelin (Egrifta™) is a synthetic analog of human growth hormone-releasing hormone (also known as growth hormone-releasing factor) that stimulates the synthesis and release of endogenous growth hormone. It is the first and, so far, only treatment indicated for the reduction of excess abdominal fat in patients with HIV-associated lipodystrophy. This article reviews the pharmacological properties, clinical efficacy and tolerability of tesamorelin in patients with HIV-associated central fat accumulation. Subcutaneous tesamorelin was effective in reducing visceral adipose tissue (VAT), but did not affect subcutaneous adipose tissue to a clinically significant extent in two 26-week, well...

Authors
Sohita Dhillon
Source
systematic_review_or_meta_analysis
DOI
10.2165/11208290-000000000-00000
PubMed
22050344
Open original source
2012Insufficient evidence
Evidence strength B · 68/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
18/100
Directness
15/100
Reporting quality
10/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy.

To evaluate the efficacy and safety of tesamorelin, a growth hormone releasing factor analogue approved by the Food and Drug Administration in November 2010 for the treatment of lipodystrophy associated with HIV infection. Literature was obtained through MEDLINE (1948-November 2011) and International Pharmaceutical Abstracts (1970-October 2011) using the search terms tesamorelin, TH9507, growth hormone releasing factor, and HIV-associated lipodystrophy syndrome. Additional publications were obtained through review of references within primary literature publications as well as pertinent Web sites. All articles published in English identified from the data sources were evaluated and all...

Authors
Linda M Spooner, Jacqueline L Olin
Source
systematic_review_or_meta_analysis
DOI
10.1345/aph.1Q629
PubMed
22298602
Open original source
2009Insufficient evidence
Evidence strength B · 68/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
18/100
Directness
15/100
Reporting quality
10/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Tesamorelin, a human growth hormone releasing factor analogue.

The combination of clinical effectiveness with a variety of adverse side effects from the use of recombinant human growth hormone (rhGH) in therapy for growth hormone (GH)-deficient disorders has led to the development of human growth hormone releasing factor (GFR) analogues, which may be better tolerated. Tesamorelin, a synthetic GFR, has been developed as a potential treatment for a variety of conditions that may be associated with a relative deficiency of GH including HIV-related lipodystrophy. This article reviews the development of tesamorelin and its purported role in HIV-related lipodystrophy and other potential indications. Relevant articles and abstracts were obtained from...

Authors
Ying Wang, Brian Tomlinson
Source
systematic_review_or_meta_analysis
DOI
10.1517/13543780802707658
PubMed
19243281
Open original source
2011Insufficient evidence
Evidence strength B · 68/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
18/100
Directness
15/100
Reporting quality
10/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy.

Tesamorelin (Egrifta™) is a synthetic analogue of human growth hormone-releasing hormone (also known as growth hormone-releasing factor) that stimulates the synthesis and release of endogenous growth hormone. It is the first and, so far, only treatment indicated for the reduction of excess abdominal fat in patients with HIV-associated lipodystrophy. This article reviews the pharmacological properties, clinical efficacy and tolerability of tesamorelin in patients with HIV-associated central fat accumulation. Subcutaneous tesamorelin was effective in reducing visceral adipose tissue (VAT), but did not affect subcutaneous adipose tissue to a clinically significant extent in two 26-week,...

Authors
Sohita Dhillon
Source
systematic_review_or_meta_analysis
DOI
10.2165/11202240-000000000-00000
PubMed
21668043
Open original source
2006Insufficient evidence
Evidence strength C · 63/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
18/100
Directness
15/100
Reporting quality
10/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor.

Theratechnologies, under license from Valeant, is developing tesamorelin as a potential vaccine adjuvant and for the potential treatment of wasting, hip fracture recovery, immune disorders, HIV-related lipodystrophy, sleep maintenance insomnia and mild cognitive impairment. Phase III clinical trials for the treatment of HIV-associated lipodystrophy and phase II clinical trials for sleep disorder, chronic obstructive pulmonary disorder, hip fracture and immune system dysfunction are underway. Phase II trials are also assessing the influenza vaccination immune response and cognitive effects of tesamorelin.

Authors
Brian Tomlinson
Source
systematic_review_or_meta_analysis
PubMed
17086939
Open original source

Scientific context

Chemistry and represented biological context

Existing reviewed chemistry is preserved as scientific context. Chemistry and mechanism information do not establish clinical efficacy or safety.

Open chemistry and biological context ↓
Chemical identity

Molecular and structural record

Structured record
Molecular formula
C221H366N72O67S
Molecular weight (Da)
5135.9

Chemical identity describes the recorded molecular information. It does not establish biological activity, clinical efficacy, safety, or therapeutic suitability.

Explore further

Continue through the research system

Move from this peptide record into the project's broader evidence, research, comparison, and methodology systems.

Research discovery

Compare peptides

Examine represented peptide records side by side.

Evidence system

Explore how scientific evidence is represented and reviewed.

Research hub

Enter the broader research and intelligence environment.

Methodology

Review project methods, boundaries, and interpretation rules.

Research

How the scientific record is developing

Chronology, unresolved research questions, opportunities, and researcher activity remain descriptive rather than evaluative.

Research chronology

  1. 2006 · study · Temporal status not established

    Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor.

    systematic_review_or_meta_analysis

  2. 2007 · study · Temporal status not established

    Metabolic Effects of a Growth Hormone–Releasing Factor in Patients with HIV

    peer_reviewed_research

  3. 2008 · study · Temporal status not established

    Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.

    peer_reviewed_research

  4. 2009 · study · Temporal status not established

    Tesamorelin, a human growth hormone releasing factor analogue.

    systematic_review_or_meta_analysis

  5. 2010 · study · Temporal status not established

    Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension

    peer_reviewed_research

  6. 2011 · study · Temporal status not established

    Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction.

    peer_reviewed_research

  7. 2011 · study · Temporal status not established

    Spotlight on tesamorelin in HIV-associated lipodystrophy.

    systematic_review_or_meta_analysis

  8. 2011 · study · Temporal status not established

    Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy.

    systematic_review_or_meta_analysis

  9. 2012 · study · Temporal status not established

    Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.

    peer_reviewed_research

  10. 2012 · study · Temporal status not established

    Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial

    peer_reviewed_research

  11. 2012 · study · Temporal status not established

    Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy.

    systematic_review_or_meta_analysis

  12. 2014 · study · Temporal status not established

    The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH.

    peer_reviewed_research

  13. 2014 · study · Temporal status not established

    Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial

    peer_reviewed_research

  14. 2015 · study · Temporal status not established

    Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects.

    peer_reviewed_research

  15. 2015 · study · Temporal status not established

    Population pharmacokinetic and pharmacodynamic analysis of tesamorelin in HIV-infected patients and healthy subjects.

    peer_reviewed_research

  16. 2015 · study · Temporal status not established

    Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat.

    peer_reviewed_research

  17. 2017 · study · Temporal status not established

    Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial.

    peer_reviewed_research

  18. 2019 · study · Temporal status not established

    The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV.

    peer_reviewed_research

  19. 2019 · study · Temporal status not established

    Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial

    peer_reviewed_research

  20. 2020 · study · Temporal status not established

    Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD.

    peer_reviewed_research

  21. 2024 · study · Temporal status not established

    Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors.

    peer_reviewed_research

  22. 2025 · study · Temporal status not established

    EGRIFTA (tesamorelin acetate) prescribing information, revised March 2025

    official_product_labeling

  23. 2025 · study · Temporal status not established

    Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity.

    peer_reviewed_research

  24. 2026 · study · Temporal status not established

    Efficacy and Safety of Tesamorelin in People Living With HIV (PLWH) With Lipodystrophy: A Systematic Review and Meta-Analysis.

    systematic_review_or_meta_analysis

  25. 2026 · study · Temporal status not established

    Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials.

    systematic_review_or_meta_analysis

  26. 2026 · regulatory · Temporal status not established

    Regulatory review: approved

    United States

The represented chronology reflects records currently included in the governed dataset and does not claim to represent the entire scientific literature.

What still needs investigation

Claim traceability

No institutional claim record is currently represented for this peptide.

Evidence is missing or not represented as studied; this is not a conclusion that the intervention does not work.

Researchers represented in the evidence record12 bibliographic identities · open to inspect

These are bibliographic author identities derived from represented records. Name strings are not proof of unique real-world researcher identity, and publishing organizations are not treated as institutional affiliations.

Jean-Claude Mamputu

7 represented evidence records

Years represented: 2008, 2011, 2012, 2015, 2017

Publishing organizations appearing in records: peer_reviewed_research

Julian Falutz

4 represented evidence records

Years represented: 2008, 2011, 2012, 2015

Publishing organizations appearing in records: peer_reviewed_research

Takara L Stanley

3 represented evidence records

Years represented: 2011, 2012, 2024

Publishing organizations appearing in records: peer_reviewed_research

Brian Tomlinson

2 represented evidence records

Years represented: 2006, 2009

Publishing organizations appearing in records: systematic_review_or_meta_analysis

Diane Potvin

2 represented evidence records

Years represented: 2008, 2011

Publishing organizations appearing in records: peer_reviewed_research

Graziella Soulban

2 represented evidence records

Years represented: 2011, 2012

Publishing organizations appearing in records: peer_reviewed_research

Meghan N Feldpausch

2 represented evidence records

Years represented: 2014, 2020

Publishing organizations appearing in records: peer_reviewed_research

Steven K Grinspoon

2 represented evidence records

Years represented: 2011, 2014

Publishing organizations appearing in records: peer_reviewed_research

A Sanyal

1 represented evidence record

Years represented: 2019

Publishing organizations appearing in records: peer_reviewed_research

A Scherzinger

1 represented evidence record

Years represented: 2019

Publishing organizations appearing in records: peer_reviewed_research

Abdulrhman Helal

1 represented evidence record

Years represented: 2026

Publishing organizations appearing in records: systematic_review_or_meta_analysis

Ahmed Samy Badran

1 represented evidence record

Years represented: 2026

Publishing organizations appearing in records: systematic_review_or_meta_analysis

Connections

Follow the scientific relationships

Connections appear only when they are represented by the project’s underlying records.

Open 3 represented connections ↓

institution

peer_reviewed_research

represented evidence source

institution

systematic_review_or_meta_analysis

represented evidence source

institution

official_product_labeling

represented evidence source

Traceability

Follow the record back to its source

The experience makes incomplete links visible instead of presenting a false impression of perfect provenance.

Source publication state

A governed source may be verified and approved for publication while its claim-to-evidence link is still incomplete.

Reviewer provenance state

“Human scientist reviewed: no” means that specific source-path attribution is not recorded. It does not silently negate the separate publication-review state.

Domain conclusion → Evidence

Connected

Evidence → Source

Connected

Source → Original record

Connected

Traceability documents how the project connects statements to records. It does not establish that a source is scientifically valid or that a claim is clinically true.

Reconciled for 13 domain conclusions and 26 featured studies.

Detailed study-to-domain mappings and original-source paths appear in the Tesamorelin evidence-governance section.

Inspect the ranked source records

Observational archive

What contributors reported

Observational archive data is intentionally separated from published scientific evidence.

Observational boundary

Insufficient eligible observations are available for display under the current filters.

Insufficient eligible observations are currently represented to display aggregated findings for this peptide.

Regulatory context

Published jurisdictional records

Regulatory status is jurisdiction-specific and time-dependent. It is presented as context, not as a recommendation for use or a substitute for scientific evidence evaluation.

Research + media

Media connected to this scientific record

Only media explicitly linked through the project’s relationship system appears here.

No scientifically connected media is currently represented for this peptide.

Sources + provenance

Read the scientific record with its boundaries intact

The public record organizes reviewed evidence; it does not establish scientific truth by itself.
Association, mechanism, observation and regulatory status must not be represented as proof of clinical efficacy or safety.
Observational reports describe contributor experiences and cannot establish causation, effectiveness, safety or clinical benefit.
Contradictory and qualifying evidence must remain visible rather than being silently discarded.
Absence of represented evidence is not evidence that research does not exist.
Research gaps identify unresolved questions; they are not negative conclusions.
Regulatory status is distinct from scientific evidence quality.
Media relationships provide context and explanation; they do not increase the strength of scientific evidence.
A section with no represented records is an incomplete project record, not a scientific conclusion.
Researcher and institutional relationships are shown only when supported by represented records and must not be interpreted as rankings or endorsements.

Generated: 11/8/2026, 5:28:49 PM

global evidence atlas

Tesamorelin research, ranked and separated by purpose

This is a deduplicated literature screening registry—not a claim that every mention directly proves efficacy or safety. Machine proposals remain visibly separate from governed human appraisal.

104Discoverable source universe
104Ranked screening records
13Research domains
28Governed published sources

104 matching records · ranked 2026-09-18

Page 1 of 5

#7Proposed tier Arandomized trialAwaiting human appraisal

Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.

The Journal of clinical endocrinology and metabolism · 2010 Sep · PMID 20554713 · DOI 10.1210/jc.2010-0490

Visceral adipose tissue · Growth-hormone axis · Long-term outcomes · Safety and tolerability · Ongoing development

Count reconciliation: 104 discoverable source records match the peptide identity query; 104 are retained in this bounded, ranked screening view; 28 belong to the separate governed layer labeled “Governed published sources.” Domain totals overlap because one publication may inform several questions.

Tesamorelin evidence · ranking key

How evidence is ranked

A tier describes the evidentiary role and design strength of a source. It is not a popularity score, proof that every conclusion is correct, or a substitute for claim-level review.

A

Practice-defining evidence

Large, well-conducted randomized trials; prespecified major outcomes; rigorous systematic reviews or meta-analyses; and major regulatory assessments.

B

Strong supporting evidence

Smaller randomized trials, strong prospective cohorts, prespecified secondary analyses, and high-quality comparative-effectiveness studies.

C

Contextual evidence

Retrospective cohorts, claims-database studies, pharmacovigilance analyses, mechanistic human research, and well-documented case series.

D

Signal-generating evidence

Case reports, conference abstracts, preclinical research, hypothesis-generating analyses, and expert commentary.

Tier and confidence answer different questions

Tier classifies source design and evidentiary role. Confidence reflects risk of bias, sample size, comparator quality, outcome relevance, follow-up, missing data, directness, replication, reporting quality, and whether conclusions stay within the measured results.

Funding and conflicts are disclosed and considered, but sponsorship never automatically changes a tier. Corrections, retractions, and expressions of concern override the original rating.

Suggested citation

  • APA

    World Peptide Foundation. (n.d.). Tesamorelin — Peptide Scientific Intelligence. World Peptide Foundation. (Reviewed September 8, 2026.) https://www.worldpeptidefoundation.org/directory/tesamorelin

  • AMA / Vancouver

    World Peptide Foundation. Tesamorelin — Peptide Scientific Intelligence. World Peptide Foundation website. Reviewed September 8, 2026. https://www.worldpeptidefoundation.org/directory/tesamorelin